With targeted and efficient expression harnessed by tissue-cancer-specific promoter and VP16-GAL4-WPRE integrated systemic amplifier, BikDD as a therapeutic gene successfully eradicated pancreatic, lung and breast tumors in preclinical cancer models with virtually no toxicity [15], [16], [19], [20]. Here, LGALS4 is linked to cancer.